Diabetes Leadership Council and Diabetes Patient Advocacy Coalition Applaud Announcement by Administration for Increased Access to GLP-1 Drugs
November 7, 2025
The Diabetes Leadership Council (DLC) and Diabetes Patient Advocacy Coalition (DPAC) applaud the announcement today by the Trump administration to reduce prices of and improve access to GLP-1 drugs.
DLC and DPAC, along with other patient groups, have advocated for expanded access to GLP-1s to treat obesity for years as part of comprehensive obesity care that also includes intensive behavioral therapy (IBT) and nutrition therapy as well as metabolic and bariatric surgery. In a poll conducted by DPAC earlier this year, 73% of those polled supported Medicare and Medicaid coverage of GLP-1 medications, including a majority of Republicans, Democrats, and Independents alike.
“DLC is encouraged by the announcement to make these drugs more affordable and accessible to millions of Americans,” stated DLC Board Chair Stewart Perry. Obesity rates in the U.S. have increased dramatically over the last 30 years, leaving Americans vulnerable to more than 200 other serious health conditions including diabetes, heart disease, high blood pressure, and stroke. “Failing to treat obesity as a recognized chronic disease only leads to worse health outcomes for Americans,” said Hunter Limbaugh, DPAC Board Chair. “This announcement is a step in the right direction.” DLC and DPAC continue to support the Treat and Reduce Obesity Act (TROA) which would ensure Medicare access to the full range of obesity care and update the IBT benefit in Medicare.